We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
ESTRO
Menu
  • Corporate Members
  • E-Library
  • Twitter
  • Linked In
  • Facebook
  • Instagram
  • Join
  • MyESTRO
Search Opener
  • About ESTRO
  • Membership
  • School
  • Workshops
  • Congresses
  • Science
  • Education
  • Advocacy
  • Corporate Members
  • E-Library
  1. Home
  2. About ESTRO
  3. Newsroom
  4. Newsletter
  5. Read it before your patients

Achieve recognition of all radiotherapy professions

Read it before your patients
  • 28/03/2025

    Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

  • 21/03/2025

    Preoperative Chemoradiotherapy for Resectable Gastric Cancer

  • 18/03/2025

    Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis

  • 14/03/2025

    Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study

  • 14/02/2025

    Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial

  • 31/01/2025

    Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma

News Pages: 1 2 3 4 5 6 7 8 9 10
  • Newsletter 2019
  • Newsletter 2018
  • Newsletter 2017

Corner Editor: Philippe Lambin

Submit your article

Corner Editor: Evert van Limbergen

Submit your article
  • Contact
  • Privacy Statement
  • Sitemap
  • Careers
  • FAQ
  • Twitter
  • Linked In
  • Facebook
  • Instagram

© The European SocieTy for Radiotherapy and Oncology. All rights reserved. ESTRO Avenue Marnix 17, 1000 Brussels . +32 477 271 125.